Jason Duncan - Albireo Pharma Gen Officer

ALBODelisted Stock  USD 44.15  0.75  1.67%   

Insider

Jason Duncan is Gen Officer of Albireo Pharma
Age 49
Phone857 254 5555
Webhttps://www.albireopharma.com

Albireo Pharma Management Efficiency

The company has return on total asset (ROA) of (0.2494) % which means that it has lost $0.2494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9308) %, meaning that it created substantial loss on money invested by shareholders. Albireo Pharma's management efficiency ratios could be used to measure how well Albireo Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 10 M in liabilities with Debt to Equity (D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. Albireo Pharma has a current ratio of 4.4, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Albireo Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Albireo Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Albireo Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Albireo to invest in growth at high rates of return. When we think about Albireo Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

FCPA FCCAHK Electric Investments
60
C ChaplinMGIC Investment Corp
64
Ronald WolfAerSale Corp
N/A
Jzsef VradiWizz Air Holdings
N/A
Charles McDonaldAerSale Corp
59
Yin HoHK Electric Investments
52
Yuanhang WangHK Electric Investments
N/A
Wai LLBHK Electric Investments
54
Wu KwongHK Electric Investments
58
Ian MalinWizz Air Holdings
N/A
Michael DelehantWizz Air Holdings
N/A
Greg BowlesJoby Aviation
N/A
Louis CarrCedar Fair LP
63
Seenu SarmaCedar Fair LP
N/A
Robert CareyWizz Air Holdings
N/A
Jodee KozlakMGIC Investment Corp
56
Julie SperberMGIC Investment Corp
50
Paul SciarraJoby Aviation
44
Robert NicholsAerSale Corp
68
Michael GualtieriComstock Holding Companies
N/A
Justin LangJoby Aviation
N/A
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. Albireo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 130 people. Albireo Pharma (ALBO) is traded on NASDAQ Exchange in USA and employs 130 people.

Management Performance

Albireo Pharma Leadership Team

Elected by the shareholders, the Albireo Pharma's board of directors comprises two types of representatives: Albireo Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Albireo. The board's role is to monitor Albireo Pharma's management team and ensure that shareholders' interests are well served. Albireo Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Albireo Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michelle Graham, Chief Officer
Peter Zorn, Senior Vice President - Corporate Development, General Counsel and Secretary
Brian Pereira, Independent Director
Kristina Torfgard, VP Head
Davey Scoon, Director
Stephanie Okey, Director
Pamela MPH, Chief Officer
Anne Klibanski, Director
Denise ScotsKnight, Director
Jason Duncan, Gen Officer
Thomas Shea, CFO, Treasurer
Pamela Stephenson, Chief Commercial Officer
Michael Gutch, Director
Joan Connolly, Chief Officer
Martha Carter, Chief Regulatory Officer
Jan Mattsson, MD Officer
David Chiswell, Chairman of the Board
Ronald Cooper, President CEO, Director
Patrick Horn, Chief Medical Officer
Simon Harford, CFO, Treasurer
Roger Jeffs, Director
Heather Preston, Director
Paresh Soni, Chief Medical Officer
PerGoran Gillberg, CoFounder Devel
Julia Brown, Independent Director

Albireo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Albireo Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Albireo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Albireo Pharma's short interest history, or implied volatility extrapolated from Albireo Pharma options trading.

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Stock

  0.69CSCO Cisco Systems Fiscal Quarter End 30th of April 2024 PairCorr
  0.66PTAIF PT Astra InternationalPairCorr
  0.64BA Boeing Fiscal Quarter End 31st of March 2024 PairCorr
  0.61EC Ecopetrol SA ADR Report 3rd of April 2024 PairCorr
  0.49PFE Pfizer Inc Fiscal Quarter End 31st of March 2024 PairCorr
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Bonds Directory
Find actively traded corporate debentures issued by US companies
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
CEOs Directory
Screen CEOs from public companies around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance